<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92359">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833754</url>
  </required_header>
  <id_info>
    <org_study_id>20110227</org_study_id>
    <nct_id>NCT01833754</nct_id>
  </id_info>
  <brief_title>Study of Romosozumab (AMG 785) Administered to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose, parallel-group study conducted in healthy subjects and
      subjects with stage 4 renal impairment (RI) or end stage renal disease (ESRD) requiring
      hemodialysis to evaluate the safety, tolerability, and immunogenicity profile of
      romosozumab. Subjects will enroll in parallel into 1 of three treatment groups to receive a
      single dose of romosozumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>• Subject incidence of treatment-emergent adverse events • Results of safety laboratory tests, vital sign measurements, and ECG measurements • Subject incidence of anti-romosozumab antibodies</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Romosozumab PK parameters</measure>
    <time_frame>15 timepoints, 85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Romosozumab serum PK parameters (ie, area under the curve [AUClast, AUCinf], maximum observed concentration [Cmax], and time to reach maximum observed concentration [tmax]): Concentration-time profiles for romosozumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 4 renal impairment (estimated glomerular filtration rate (eGFR)] 15 to 29 mL/min/1.73 m2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End stage renal disease requiring hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects (estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Subcutaneous, Single Dose, Single Dose Level</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>AMG 785</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA - ALL SUBJECTS :

          -  Males or females ≥ 50 years of age

          -  Body weight ≥ 45 and ≤ 110 kg

          -  Willing to adhere to calcium and vitamin D supplementation requirements

          -  Females must be of non-reproductive potential

        INCLUSION CRITERIA - SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2):

          -  Group 1 - Stage 4 RI (estimated glomerular filtration rate (eGFR) 15-29 mL/min/1.73
             m2)

          -  Group 2 - End stage renal disease requiring hemodialysis

        INCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3):

        • Renal function defined as an - estimated glomerular filtration rate (eGFR) ≥ 80
        mL/min/1.73 m2

        EXCLUSION CRITERIA - ALL SUBJECTS:

          -  History of metabolic or bone disease (except for metabolic bone disease in renal
             impairment (RI) subjects)

          -  History of osteoporosis, vertebral fracture, or fragility fracture of the wrist,
             humerus, hip, or pelvis after age 50

          -  Recent bone fracture

          -  Vitamin D insufficiency

          -  Hypocalcemia or hypercalcemia

          -  Hypomagnesemia

          -  Hypophosphatemia

          -  Untreated hyper- or hypothyroidism

          -  Females with a positive pregnancy test

          -  Males with pregnant partners

          -  Females who are lactating/breastfeeding or plan to breastfeed on study and for 3
             months after receiving the dose of study drug

          -  History of spinal stenosis

          -  History of facial nerve paralysis

          -  Positive for human immunodeficiency virus (HIV) antibodies

          -  Positive for hepatitis B surface antigen or detectable hepatitis C

          -  Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma,
             cervical, or breast ductal carcinoma in situ) within 5 years before screening

          -  History of solid organ or bone marrow transplants EXCLUSION CRITERIA - HEALTHY
             SUBJECTS (GROUP 3)

          -  Current hyper- or hypoparathyroidism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
